Navigation Links
Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
Date:8/24/2010

PRINCETON, N.J., Aug 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.

"We look for the Phase 2b to further support the efficacy, safety and resistance profile of PSI-7977 over 12 weeks, and to confirm a dose for continued development," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "Given the potent antiviral activity observed in the Phase 2a study and in vitro evidence for pan-genotype activity, we have also decided to include an exploratory, open label arm of patients with HCV genotype 2 and 3 who will receive a 12 week treatment regimen of PSI-7977 in combination with pegylated interferon and ribavirin. If successful, this shorter treatment regimen would be a first step toward defining a new treatment option for these patients."

About the Phase 2b TrialThe Phase 2b trial is anticipated to enroll approximately 125 patients infected with HCV genotype 1 who have not been treated previously. The primary endpoint of the trial will be the assessment of safety and tolerability of PSI-7977, in combination with SOC over 12 weeks with response-guided therapy allowing discontinuation of SOC at week 24. The trial will be conducted in the U.S. Patients will be randomized (2:2:1) into one of 3 arms:

  • PSI-7977 200mg QD in combination with SOC for 12 weeks, followed by 12 or 36 weeks of SOC;
  • PSI-7977 400mg QD in combination with SOC for 12 weeks, followed by 12 or 36 weeks of SOC;
  • A control arm of matching placebo with SOC for 48 weeks.<
    '/>"/>

  • SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
    3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
    4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
    5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
    6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
    7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
    8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
    9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
    10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
    11. Pharmasset Receives Notice of Allowance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/4/2015)... Young Innovations ("Young"), a leading global ... the acquisition of the professional dental contract manufacturing ... MPL PDCMD manufactures fluoride varnish, prophy paste and ... procedures. "This acquisition marks the ... high-growth segments," said Dave Sproat , CEO ...
    (Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... second quarter and six months ended June 30, 2015. ... in ITP are progressing and we continue to expect ... Rodriguez , president and chief executive officer of Rigel. ... other clinical programs, including evaluating fostamatinib for new treatment ...
    (Date:8/4/2015)... SEATTLE , Aug. 4, 2015  Dr. ... Institute states the potential FDA approval of flibanserin, ... sets women and the treatment of decreased female ... women has many root causes and addressing libido ... is dangerous. ...
    Breaking Medicine Technology:Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
    ... June 30, 2011 UCB and Harvard University officially ... that took place in Boston last night in the ... (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) ... industry and academia, with Harvard scientists continuing their research ...
    ... -- Golden Meditech Holdings Limited ("Golden ... "Group," - 801.HK; 910801.TW), a leading integrated healthcare ... Group,s annual results for the year ended 31 ... core businesses reported total turnover of HK$328,066,000, 15% ...
    Cached Medicine Technology:UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3Golden Meditech FY2010-11 Annual Results 2Golden Meditech FY2010-11 Annual Results 3
    (Date:8/4/2015)... ... August 05, 2015 , ... ... Stevens as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
    (Date:8/4/2015)... ... August 05, 2015 , ... The Journal of Pain ... ”. , As corresponding author Professor Akiko Okifuji says “Both obesity and chronic pain ... is not to say that one causes the other. Rather, there appear to be ...
    (Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... technology platform that uses Cloud innovation to consolidate oncology patient assistance programs. Through ... a single point of access. assistPoint is an enterprise level, cloud-based application and ...
    (Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health ... echocardiogram, and NCV testing, announced their collegiate division, Wimbledon U , continues ... abnormalities one program at a time. , “Wimbledon U welcomes the ...
    (Date:8/4/2015)... ... , ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp in ... that have a flip-up face shield. The sleek contours of the new Nightstick ... remove their headlamp when raising or lowering their face shield or visor. The 4614 ...
    Breaking Medicine News(10 mins):Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
    ... CREEK, Fla., Feb. 26 AlertSite(R), a leading,provider ... businesses,ensure optimum web experiences for their customers, announced ... site monitoring service.,iHerb.com is a major online retailer ... was recently name by ConsumerLab.com as the #1 ...
    ... Sponsorship of the 6th Annual Medical Banking Institute, highlights company,s ... ... and services platform, DALLAS, Feb. 26 BancTec, a ... is joining with,other industry leaders in an effort to improve ...
    ... as a Service, Innovation and Customer-Focused Approach to ... Artromick International, Inc.,a leading developer of medication ... acute care markets, today announced Edwin,Miller has joined ... Group.,In his new role, Miller is responsible for ...
    ... NEW YORK, Feb. 26 With over five million ... million new cases,diagnosed every year, it is the number ... accounting for a yearly direct cost of care,estimated at ... Failure: Worldwide Device Markets., Improvements in the care ...
    ... Capabilities, and New Architecture Position Solution as ... Market Leader, STAMFORD, ... the latest update to its Order Sets,Solution, which now includes:, ... market. -- Tools to create, edit, and maintain large ...
    ... Rx, a,wholly owned subsidiary of TeamStaff, Inc. ... Seal of Approval(TM) for health care staffing ... Healthcare Organizations ("JCAHO")., The JCAHO review ... processes, performance evaluations, education processes,and information management ...
    Cached Medicine News:Health News:Top Nutritional Supplement Online Retailer, iHerb.com, Selects AlertSite for Web Site Performance Monitoring 2Health News:BancTec Takes Leadership Position in Helping to Create Better Value, Lower Transaction Costs in Healthcare Industry 2Health News:BancTec Takes Leadership Position in Helping to Create Better Value, Lower Transaction Costs in Healthcare Industry 3Health News:Artromick Names Edwin Miller President of Software Products Group 2Health News:'Hidden Epidemic' of Congestive Heart Failure Driving Hospitalization, Costs 2Health News:Thomson Healthcare Announces Enhancements to Order Sets Solution 2Health News:Thomson Healthcare Announces Enhancements to Order Sets Solution 3Health News:TeamStaff Rx Awarded JCAHO Certification 2Health News:TeamStaff Rx Awarded JCAHO Certification 3
    ... is a unique microprocessor controlled shaking incubator ... either 96 or 384 well format. Speed, ... control panel and all are displayed on ... the clear protective cover. The Millennium 2000 ...
    ... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
    ... Ultracompact high end desktop multilaser flow ... any kind of cell analysis and absolute ... forward and two different side scatter signals ... channels. The new CyFlow ML instrument can ...
    This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
    Medicine Products: